The prognosis for children with cancer has improved dramatically over the past decades with an overall 5-year survival rate now at 84%. However, the late effects of cancer treatment, including permanent organ and tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the estimated 360,000 survivors of childhood cancer experiencing a significant health-related quality of life complication from childhood cancer and its treatment. In addition, progress for a number of childhood cancers remains limited with approximately 50% of children with acute myelogenous leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing to their disease. The Children?s Oncology Group (COG), the world?s largest organization devoted exclusively to childhood and adolescent cancer research, and its multidisciplinary research teams comprised of more than 9,000 members, conducts research at more than 220 leading children?s hospitals, universities, and cancer centers. This proposal is for the COG NCI Community Oncology Research Program (NCORP) Research Base to continue its collaborative research work for our 26 community and 16 minority/underserved NCORP sites. With COG?s significant scientific, statistical, data management and information technology infrastructure, we seek to conduct pediatric clinical trials to define optimal treatments, and conduct laboratory research that will translate into more effective treatments with reduced side effects. The COG directly addresses the NCORP goals of providing access to state-of-the-art cancer treatment at community sites while conducting research in cancer control, including post-treatment surveillance/survivorship, and cancer care delivery. We promote the participation of community-based investigators in all of COG?s research, governance and administration and in NCORP Network activities. The COG?s research goals are to reduce overall mortality and morbidity, decrease acute and delayed treatment-related toxicities, and develop more effective ways of delivering care to children, adolescents and young adults. The COG NCORP Research Base is uniquely positioned to elucidate the impact of different health care delivery characteristics on outcomes, to identify determinants of poorer outcomes in underserved groups including adolescents and young adults, and to develop targeted strategies aimed at eliminating disparities and improving efficiencies for the delivery of cancer care in young persons with cancer.

Public Health Relevance

The Children?s Oncology Group (COG) is the world?s largest organization devoted exclusively to childhood and adolescent cancer research with more than 9,000 members at over 220 leading children?s hospitals, universities, and cancer centers across the U.S., Canada and other countries. The COG conducts therapeutic trials as well as cancer control and cancer care delivery research studies to improve outcomes across diverse populations including adolescents and young adults with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
3UG1CA189955-07S1
Application #
10229153
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Bakos, Alexis Diane
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19146
Dupuis, L Lee; Kelly, Kara M; Krischer, Jeffrey P et al. (2018) Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial. Cancer 124:1188-1196
Zheng, Daniel J; Lu, Xiaomin; Schore, Reuven J et al. (2018) Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer 124:571-579
Landier, Wendy; Chen, Yanjun; Hageman, Lindsey et al. (2017) Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. Blood 129:1919-1926
Pole, Jason D; Gibson, Paul; Ethier, Marie-Chantal et al. (2017) Evaluation of treatment-related mortality among paediatric cancer deaths: a population based analysis. Br J Cancer 116:540-545
Treister, Nathaniel; Nieder, Michael; Baggott, Christina et al. (2017) Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation. Br J Cancer 116:21-27
Knight, Kristin R; Chen, Lu; Freyer, David et al. (2017) Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. J Clin Oncol 35:440-445
Haase, Joan E; Kintner, Eileen K; Robb, Sheri L et al. (2017) The Resilience in Illness Model Part 2: Confirmatory Evaluation in Adolescents and Young Adults With Cancer. Cancer Nurs 40:454-463
Carlos, Ruth C; Sicks, JoRean D; Chang, George J et al. (2017) Capacity for Cancer Care Delivery Research in National Cancer Institute Community Oncology Research Program Community Practices: Availability of Radiology and Primary Care Research Partners. J Am Coll Radiol 14:1530-1537
Loeffen, E A H; Kremer, L C M; Mulder, R L et al. (2017) The importance of evidence-based supportive care practice guidelines in childhood cancer-a plea for their development and implementation. Support Care Cancer 25:1121-1125
Freyer, David R; Chen, Lu; Krailo, Mark D et al. (2017) Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18:63-74

Showing the most recent 10 out of 50 publications